Update on epstein-barr virus and gastric cancer (review)

International Journal of Oncology

Volumn 46, Issue 4, 2015, Pages 1421-1434

  Shinozaki Ushiku, Aya ^a   Kunita, Akiko ^a   Fukayama, Masashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Epstein Barr virus; Gastric cancer

Indexed keywords

MICRORNA; TUMOR SUPPRESSOR PROTEIN;

CANCER EPIDEMIOLOGY; CLINICAL FEATURE; EPIGENETICS; EPITHELIUM CELL; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; GENOMICS; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; VIRUS GENE; DNA METHYLATION; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MALE; PATHOLOGY; PHYSIOLOGY; SEX DIFFERENCE; STOMACH NEOPLASMS; VIROLOGY;

DNA METHYLATION; EPIGENESIS, GENETIC; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 4, HUMAN; HUMANS; MALE; SEX FACTORS; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84923083089     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2856     Document Type: Review

References (138)

1. EPSTEIN MA, ACHONG BG and BARR YM: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1: 702-703, 1964.
2. YOUNG LS and RICKINSON AB: Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768, 2004.
3. BURKE A P, YEN TS, SHEKITKA KM and SOBIN LH: Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol 3: 377-380, 1990.
4. SHIBATA D, TOKUNAGA M, UEMURA Y, SATO E, TANAKA S and WEISS LM: Association of Epstein-Barr virus with undiffer-entiated gastric carcinomas with intense lymphoid infltration. Lymphoepithelioma-like carcinoma. Am J Pathol 139: 469-474, 1991.
5. SHIBATA D and WEISS LM: Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 140: 769-774, 1992.
6. FUKAYAMA M, HAYASHI Y, IWASAKI Y, et al: Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach. Lab Invest 71: 73-81, 1994.
7. MARSHALL BJ and WARREN JR: Unidentifed curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1: 1311-1315, 1984.
8. NOMURA A, STEMMERMANN GN, CHYOU PH, KATO I, PEREZ-PEREZ GI and BLASER MJ: Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 325: 1132-1136, 1991.
9. PARSONNET J, FRIEDMAN GD, VANDERSTEEN DP, et al: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 325: 1127-1131, 1991.
10. FUKAYAMA M and USHIKU T: Epstein-Barr virus-associated gastric carcinoma. Pathol Res Pract 207: 529-537, 2011.
11. CHEN JN, HE D, TANG F and SHAO CK: Epstein-Barr virus-associated gastric carcinoma: A newly defined entity. J Clin Gastroenterol 46: 262-271, 2012.
12. MURPHY G, PFEIFFER R, CAMARGO MC and RABKIN CS: Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric Cancer differs based on sex and anatomic location. Gastroenterology 137: 824-833, 2009.
13. CAMARGO MC, KIM WH, CHIARAVALLI AM, et al: Improved survival of gastric Cancer with tumour Epstein-Barr virus posi-tivity: An international pooled analysis. Gut 63: 236-243, 2014.
14. BOYLE P and LEVIN B: Stomach Cancer. IARC Press, Lyon, 2008.
15. CAMARGO MC, MURPHY G, KORIYAMA C, et al: Determinants of Epstein-Barr virus-positive gastric cancer: An international pooled analysis. Br J Cancer 105: 38-43, 2011.
16. LEE JH, KIM SH, HAN SH, AN JS, LEE ES and KIM YS: Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: A meta-analysis. J Gastroenterol Hepatol 24: 354-365, 2009.
17. TRUONG CD, FENG W, LI W, et al: Characteristics of Epstein-Barr virus-associated gastric cancer: A study of 235 cases at a comprehensive Cancer center in USA. J Exp Clin Cancer Res 28: 14, 2009.
18. CHEN JN, JIANG Y, LI HG, et al: Epstein-Barr virus genome polymorphisms of Epstein-Barr virus-associated gastric carcinoma in gastric remnant carcinoma in Guangzhou, southern China, an endemic area of nasopharyngeal carcinoma. Virus Res 160: 191-199, 2011.
19. KORIYAMA C, AKIBA S, MINAKAMI Y and EIZURU Y: Environmental factors related to Epstein-Barr virus-associated gastric Cancer in Japan. J Exp Clin Cancer Res 24: 547-553, 2005.
20. CAMARGO MC, KORIYAMA C, MATSUO K, et al: Case-case comparison of smoking and alcohol risk associations with Epstein-Barr virus-positive gastric cancer. Int J Cancer 134: 948-953, 2014.
21. VAN BEEK J, ZUR HAUSEN A, KLEIN KRANENBARG E, et al: EBV-positive gastric adenocarcinomas: A distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol 22: 664-670, 2004.
22. TOKUNAGA M and LAND CE: Epstein-Barr virus involvement in gastric cancer: Biomarker for lymph node metastasis. Cancer Epidemiol Biomarkers Prev 7: 449-450, 1998.
23. MATSUNOU H, KONISHI F, HORI H, et al: Characteristics of Epstein-Barr virus-associated gastric carcinoma with lymphoid stroma in Japan. Cancer 77: 1998-2004, 1996.
24. SONG HJ, SRIVASTAVA A, LEE J, et al: Host infammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology 139: 84-92.e82, 2010.
25. KORIYAMA C, AKIBA S, ITOH T, et al: Prognostic signifcance of Epstein-Barr virus involvement in gastric carcinoma in Japan. Int J Mol Med 10: 635-639, 2002.
26. KIJIMA Y, ISHIGAMI S, HOKITA S, et al: The comparison of the prognosis between Epstein-Barr virus (EBV)-positive gastric carcinomas and EBV-negative ones. Cancer Lett 200: 33-40, 2003.
27. TOKUNAGA M, LAND CE, UEMURA Y, TOKUDOME T, TANAKA S and SATO E: Epstein-Barr virus in gastric carcinoma. Am J Pathol 143: 1250-1254, 1993.
28. CHANG MS, LEE HS, KIM HS, et al: Epstein-Barr virus and microsatellite instability in gastric carcinogenesis. J Pathol 199: 447-452, 2003.
29. KAIZAKI Y, HOSOKAWA O, SAKURAI S and FUKAYAMA M: Epstein-Barr virus-associated gastric carcinoma in the remnant stomach: De novo and metachronous gastric remnant carcinoma. J Gastroenterol 40: 570-577, 2005.
30. LEE JY, KIM KM, MIN BH, LEE JH, RHEE PL and KIM JJ: Epstein-Barr virus-associated lymphoepithelioma-like early gastric carcinomas and endoscopic submucosal dissection: Case series. World J Gastroenterol 20: 1365-1370, 2014.
31. NAKAMURA S, UEKI T, YAO T, UEYAMA T and TSUNEYOSHI M: Epstein-Barr virus in gastric carcinoma with lymphoid stroma. Special reference to its detection by the polymerase chain reaction and in situ hybridization in 99 tumors, including a morphologic analysis. Cancer 73: 2239-2249, 1994.
32. WATANABE H, ENJOJI M and IMAI T: Gastric carcinoma with lymphoid stroma. Its morphologic characteristics and prognostic correlations. Cancer 38: 232-243, 1976.
33. LAUREN P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classifcation. Acta Pathol Microbiol Scand 64: 31-49, 1965.
34. SONG HJ and KIM KM: Pathology of epstein-barr virus-associated gastric carcinoma and its relationship to prognosis. Gut Liver 5: 143-148, 2011.
35. SHINOZAKI A, USHIKU T, MORIKAWA T, et al: Epstein-Barr virus-associated gastric carcinoma: A distinct carcinoma of gastric phenotype by claudin expression profling. J Histochem Cytochem 57: 775-785, 2009.
36. VAN BEEK J, ZUR HAUSEN A, SNEL SN, et al: Morphological evidence of an activated cytotoxic T-cell infltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol 30: 59-65, 2006.
37. + cytotoxic T lymphocytes infltrating an Epstein-Barr virus-associated gastric carcinoma. J Clin Invest 104: 163-171, 1999.
38. SHINOZAKI A, USHIKU T and FUKAYAMA M: Prominent Mott Cell proliferation in Epstein-Barr virus-associated gastric carcinoma. Hum Pathol 41: 134-138, 2009.
39. USHIKU T, SHINOZAKI A, UOZAKI H, et al: Gastric carcinoma with osteoclast-like giant cells. Lymphoepithelioma-like carcinoma with Epstein-Barr virus infection is the predominant type. Pathol Int 60: 551-558, 2010.
40. CHOI MG, JEONG JY, KIM KM, et al: Clinical signifcance of gastritis cystica profunda and its association with Epstein-Barr virus in gastric cancer. Cancer 118: 5227-5233, 2012.
41. TSAO SW, TSANG CM, PANG PS, ZHANG G, CHEN H and LO KW: The biology of EBV infection in human epithelial cells. Semin Cancer Biol 22: 137-143, 2012.
42. RICKINSON AB: Co-infections, infammation and oncogenesis: Future directions for EBV research. Semin Cancer Biol 26: 99-115, 2014.
43. IMAI S, NISHIKAWA J and TAKADA K: Cell-to-cell contact as an effcient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 72: 4371-4378, 1998.
44. HAYASHI K, TERAMOTO N, AKAGI T, SASAKI Y and SUZUKI T: In situ detection of Epstein-Barr virus in the gastric glands with intestinal metaplasia. Am J Gastroenterol 91: 1481, 1996.
45. SUGIURA M, IMAI S, TOKUNAGA M, et al: Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: Unique viral latency in the tumour cells. Br J Cancer 74: 625-631, 1996.
46. LUO B, WANG Y, WANG XF, et al: Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. World J Gastroenterol 11: 629-633, 2005.
47. STRONG MJ, XU G, COCO J, et al: Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: Implications for possible immune adjuvant therapy. PLoS Pathog 9: E1003341, 2013.
48. TANG W, MORGAN DR, MEYERS MO, et al: Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profle. Infect Agent Cancer 7: 21, 2012.
49. SHANNON-LOWE C, ADLAND E, BELL AI, DELECLUSE HJ, RICKINSON AB and ROWE M: Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: Viral genome expression, genome maintenance, and genome amplification. J Virol 83: 7749-7760, 2009.
50. IWAKIRI D and TAKADA K: Role of EBERs in the pathogenesis of EBV infection. Adv Cancer Res 107: 119-136, 2010.
51. IWAKIRI D, EIZURU Y, TOKUNAGA M and TAKADA K: Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Cancer Res 63: 7062-7067, 2003.
52. SHINOZAKI A, SAKATANI T, USHIKU T, et al: Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res 70: 4719-4727, 2010.
53. BANERJEE AS, PAL AD and BANERJEE S: Epstein-Barr virus-encoded small non-coding RNAs induce Cancer Cell chemoresistance and migration. Virology 443: 294-305, 2013.
54. GRUHNE B, SOMPALLAE R, MARESCOTTI D, KAMRANVAR SA, GASTALDELLO S and MASUCCI MG: The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc Natl Acad Sci USA 106: 2313-2318, 2009.
55. LU J, MURAKAMI M, VERMA SC, et al: Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin. Virology 410: 64-75, 2011.
56. SARIDAKIS V, SHENG Y, SARKARI F, et al: Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell 18: 25-36, 2005.
57. CHENG TC, HSIEH SS, HSU WL, CHEN YF, HO HH and SHEU LF: Expression of Epstein-Barr nuclear antigen 1 in gastric carcinoma cells is associated with enhanced tumorigenicity and reduced cisplatin sensitivity. Int J Oncol 36: 151-160, 2010.
58. SIVACHANDRAN N, DAWSON CW, YOUNG LS, LIU FF, MIDDELDORP J and FRAPPIER L: Contributions of the Epstein-Barr virus EBNA1 protein to gastric carcinoma. J Virol 86: 60-68, 2012.
59. YIN Q and FLEMINGTON EK: Sirnas against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology 346: 385-393, 2006.
60. HONG M, MURAI Y, KUTSUNA T, et al: Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells. J Cancer Res Clin Oncol 132: 1-8, 2006.
61. IAN MX, LAN SZ, CHENG ZF, DAN H and QIONG LH: Suppression of EBNA1 expression inhibits growth of EBV-positive NK/T Cell lymphoma cells. Cancer Biol Ther 7: 1602-1606, 2008.
62. FUKUDA M, IKUTA K, YANAGIHARA K, et al: Effect of transforming growth factor-beta1 on the Cell growth and Epstein-Barr virus reactivation in EBV-infected epithelial Cell lines. Virology 288: 109-118, 2001.
63. HINO R, UOZAKI H, INOUE Y, et al: Survival advantage of EBV-associated gastric carcinoma: Survivin up-regulation by viral latent membrane protein 2A. Cancer Res 68: 1427-1435, 2008.
64. LIU X, GAO Y, LUO B and ZHAO Y: Construction and antiapoptosis activities of recombinant adenoviral Expression vector carrying EBV latent membrane protein 2A. Gastroenterol Res Pract 2011: 182832, 2011.
65. PAL AD, BASAK NP, BANERJEE AS and BANERJEE S: Epstein-Barr virus latent membrane protein-2A alters mitochondrial dynamics promoting cellular migration mediated by Notch signaling pathway. Carcinogenesis 35: 1592-1601, 2014.
66. HINO R, UOZAKI H, MURAKAMI N, et al: Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 69: 2766-2774, 2009.
67. ZHAO J, LIANG Q, CHEUNG KF, et al: Genome-wide identifcation of Epstein-Barr virus-driven promoter methylation profles of human genes in gastric Cancer cells. Cancer 119: 304-312, 2013.
68. AL-MOZAINI M, BODELON G, KARSTEGL CE, JIN B, AL-AHDAL M and FARRELL PJ: Epstein-Barr virus BART gene expression. J Gen Virol 90: 307-316, 2009.
69. THORNBURG NJ, KUSANO S and RAAB-TRAUB N: Identifcation of Epstein-Barr virus RK-BARF0-interacting proteins and characterization of expression pattern. J Virol 78: 12848-12856, 2004.
70. HOEBE EK, LE LARGE TY, GREIJER AE and MIDDELDORP JM: BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator. Rev Med Virol 23: 367-383, 2013.
71. ZUR HAUSEN A, BRINK AA, CRAANEN ME, MIDDELDORP JM, MEIJER CJ and VAN DEN BRULE AJ: Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarci-nomas: Expression of the transforming BARF1 gene. Cancer Res 60: 2745-2748, 2000.
72. WANG Q, TSAO SW, OOKA T, et al: Anti-apoptotic role of BARF1 in gastric Cancer cells. Cancer Lett 238: 90-103, 2006.
73. WIECH T, NIKOLOPOULOS E, LASSMAN S, et al: Cyclin D1 expression is induced by viral BARF1 and is overexpressed in EBV-associated gastric cancer. Virchows Arch 452: 621-627, 2008.
74. CHANG MS, KIM DH, ROH JK, et al: Epstein-Barr virus-encoded BARF1 promotes proliferation of gastric carcinoma cells through regulation of NF-kappaB. J Virol 87: 10515-10523, 2013.
75. KANEDA A, MATSUSAKA K, ABURATANI H and FUKAYAMA M: Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res 72: 3445-3450, 2012.
76. MATSUSAKA K, FUNATA S, FUKAYAMA M and KANEDA A: DNA methylation in gastric cancer, related to Helicobacter pylori and Epstein-Barr virus. World J Gastroenterol 20: 3916-3926, 2014.
77. YAU TO, TANG CM and YU J: Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: Disease and treatments. World J Gastroenterol 20: 6448-6456, 2014.
78. KUSANO M, TOYOTA M, SUZUKI H, et al: Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 106: 1467-1479, 2006.
79. ZONG L and SETO Y: CpG island methylator phenotype, helico-bacter pylori, Epstein-Barr virus, and microsatellite instability and prognosis in gastric cancer: A systematic review and meta-analysis. PLoS One 9: E86097, 2014.
80. OKADA T, NAKAMURA M, NISHIKAWA J, et al: Identifcation of genes specifcally methylated in Epstein-Barr virus-associated gastric carcinomas. Cancer Sci 104: 1309-1314, 2013.
81. SAITO M, NISHIKAWA J, OKADA T, et al: Role of DNA methyla-tion in the development of Epstein-Barr virus-associated gastric carcinoma. J Med Virol 85: 121-127, 2013.
82. CHAPEL F, FABIANI B, DAVI F, et al: Epstein-Barr virus and gastric carcinoma in Western patients: Comparison of pathological parameters and p53 expression in EBV-positive and negative tumours. Histopathology 36: 252-261, 2000.
83. MATSUSAKA K, KANEDA A, NAGAE G, et al: Classification of Epstein-Barr virus-positive gastric cancers by defnition of DNA methylation epigenotypes. Cancer Res 71: 7187-7197, 2011.
84. ZUR HAUSEN A, VAN GRIEKEN NC, MEIJER GA, et al: Distinct chromosomal aberrations in Epstein-Barr virus-carrying gastric carcinomas tested by comparative genomic hybridization. Gastroenterology 121: 612-618, 2001.
85. CHAN W Y, LIU Y, LI CY, et al: Recurrent genomic aberrations in gastric carcinomas associated with Helicobacter pylori and Epstein-Barr virus. Diagn Mol Pathol 11: 127-134, 2002.
86. CHONG JM, FUKAYAMA M, HAYASHI Y, et al: Microsatellite instability in the progression of gastric carcinoma. Cancer Res 54: 4595-4597, 1994.
87. LEE J, VAN HUMMELEN P, GO C, et al: High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One 7: E38892, 2012.
88. SUKAWA Y, YAMAMOTO H, NOSHO K, et al: Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterol 18: 6577-6586, 2012.
89. The Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513: 202-209, 2014.
90. LIANG Q, YAO X, TANG S, et al: Integrative identification of epstein-barr virus-associated mutations and epigenetic alterations in gastric cancer. Gastroenterology 147: 1350-1362.e1354, 2014.
91. WANG K, KAN J, YUEN ST, et al: Exome sequencing identifes frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 43: 1219-1223, 2011.
92. ABE H, MAEDA D, HINO R, et al: ARID1A expression loss in gastric cancer: Pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch 461: 367-377, 2012.
93. MORITANI S, SUGIHARA H, KUSHIMA R and HATTORI T: Different roles of p53 between Epstein-Barr virus-positive and-negative gastric carcinomas of matched histology. Virchows Arch 440: 367-375, 2002.
94. PARK HY, KANG SY, KANG GH, et al: EBV infection and mismatch repair defciency mediated by loss of hMLH1 expression contribute independently to the development of multiple synchronous gastric carcinomas. J Surg Oncol 106: 777-782, 2012.
95. DOLAN DE and GUPTA S: PD-1 pathway inhibitors: Changing the landscape of Cancer immunotherapy. Cancer Control 21: 231-237, 2014.
96. NAIDOO J, PAGE DB and WOLCHOK JD: Immune modulation for Cancer therapy. Br J Cancer 11: 2214-2219, 2014.
97. MARQUITZ AR, MATHUR A, SHAIR KH and RAAB-TRAUB N: Infection of Epstein-Barr virus in a gastric carcinoma Cell line induces anchorage independence and global changes in gene expression. Proc Natl Acad Sci USA 109: 9593-9598, 2012.
98. KIM SY, PARK C, KIM HJ, et al: Deregulation of immune response genes in patients with Epstein-Barr virus-associated gastric Cancer and outcomes. Gastroenterology 148: 137-147.e139, 2014.
99. CHEN BJ, CHAPUY B, OUYANG J, et al: PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19: 3462-3473, 2013.
100. GREEN MR, RODIG S, JUSZCZYNSKI P, et al: Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy. Clin Cancer Res 18: 1611-1618, 2012.
101. KIM DO N and LEE SK: Biogenesis of Epstein-Barr virus microRNAs. Mol Cell Biochem 365: 203-210, 2012.
102. PFEFFER S, ZAVOLAN M, GRASSER FA, et al: Identifcation of virus-encoded microRNAs. Science 304: 734-736, 2004.
103. BARTH S, MEISTER G and GRASSER FA: EBV-encoded miRNAs. Biochim Biophys Acta 1809: 631-640, 2011.
104. CHAN JY, GAO W, HO WK, WEI WI and WONG TS: Overexpression of Epstein-Barr virus-encoded microRNA-BART7 in undif-ferentiated nasopharyngeal carcinoma. Anticancer Res 32: 3201-3210, 2012.
105. CHEN SJ, CHEN GH, CHEN YH, et al: Characterization of Epstein-Barr virus miRNAome in nasopharyngeal carcinoma by deep sequencing. PLoS One 5: E12745, 2010.
106. CHOI H, LEE H, KIM SR, GHO YS and LEE SK: Epstein-Barr virus-encoded microRNA BART15-3p promotes Cell apoptosis partially by targeting BRUCE. J Virol 87: 8135-8144, 2013.
107. CHOY EY, SIU KL, KOK KH, et al: An Epstein-Barr virus-encoded microRNA targets PUMA to promote host Cell survival. J Exp Med 205: 2551-2560, 2008.
108. COSMOPOULOS K, PEGTEL M, HAWKINS J, et al: Comprehensive profling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol 83: 2357-2367, 2009.
109. GOURZONES C, GELIN A, BOMBIK I, et al: Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells. Virol J 7: 271, 2010.
110. GOURZONES C, FERRAND FR, AMIEL C, et al: Consistent high concentration of the viral microRNA BART17 in plasma samples from nasopharyngeal carcinoma patients-evidence of non-exosomal transport. Virol J 10: 119, 2013.
111. IMIG J, MOTSCH N, ZHU J Y, et al: Microrna profling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res 39: 1880-1893, 2011.
112. LUNG RW, TONG JH and TO KF: Emerging roles of small Epstein-Barr virus derived non-coding RNAs in epithelial malignancy. Int J Mol Sci 14: 17378-17409, 2013.
113. MARQUITZ AR, MATHUR A, NAM CS and RAAB-TRAUB N: The Epstein-Barr Virus BART microRNAs target the pro-apoptotic protein Bim. Virology 412: 392-400, 2011.
114. MOTSCH N, ALLES J, IMIG J, et al: MicroRNA profiling of Epstein-Barr virus-associated NK/T-cell lymphomas by deep sequencing. PLoS One 7: E42193, 2012.
115. NOURSE J P, CROOKS P, KEANE C, et al: Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fxed primary Epstein-Barr virus-positive B-cell lymphoma samples. J Virol Methods 184: 46-54, 2012.
116. RILEY KJ, RABINOWITZ GS, YARIO TA, LUNA JM, DARNELL RB and STEITZ JA: EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency. EMBO J 31: 2207-2221, 2012.
117. VEREIDE DT, SETO E, CHIU Y F, et al: Epstein-Barr virus maintains lymphomas via its miRNAs. Oncogene 33: 1258-1264, 2014.
118. WONG AM, KONG KL, TSANG JW, KWONG DL and GUAN XY: Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer 118: 698-710, 2011.
119. XIA T, O'HARA A, ARAUJO I, et al: EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res 68: 1436-1442, 2008.
120. ZHU JY, PFUHL T, MOTSCH N, et al: Identifcat ion of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. J Virol 83: 3333-3341, 2009.
121. QIU J and THORLEY-LAWSON DA: EBV microRNA BART 18-5p targets MAP3K2 to facilitate persistence in vivo by inhibiting viral replication in B cells. Proc Natl Acad Sci USA 111: 11157-11162, 2014.
122. KIM DO N, CHAE HS, OH ST, et al: Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J Virol 81: 1033-1036, 2007.
123. MARQUITZ AR, MATHUR A, CHUGH PE, DITTMER DP and RAAB-TRAUB N: Expression profile of microRNAs in Epstein-Barr virus-infected AGS gastric carcinoma cells. J Virol 88: 1389-1393, 2014.
124. KIM DO N, SEO MK, CHOI H, et al: Characterization of naturally Epstein-Barr virus-infected gastric carcinoma Cell line YCCEL1. J Gen Virol 94: 497-506, 2013.
125. QIU J, COSMOPOULOS K, PEGTEL M, et al: A novel persistence associated EBV miRNA expression profle is disrupted in neoplasia. PLoS Pathog 7: E1002193, 2011.
126. SKALSKY RL, CORCORAN DL, GOTTWEIN E, et al: The viral and cellular microRNA targetome in lymphoblastoid Cell lines. PLoS Pathog 8: E1002484, 2012.
127. LO AK, TO KF, LO KW, et al: Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U SA 104: 16164-16169, 2007.
128. BARTH S, PFUHL T, MAMIANI A, et al: Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA poly-merase BALF5. Nucleic Acids Res 36: 666-675, 2008.
129. DOLKEN L, MALTERER G, ERHARD F, et al: Systematic analysis of viral and cellular microRNA targets in cells latently infected with human gamma-herpesviruses by RISC immunoprecipita-tion assay. Cell Host Microbe 7: 324-334, 2010.
130. IIZASA H, WULFF BE, ALLA NR, et al: Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem 285: 33358-33370, 2010.
131. AMBROSIO MR, NAVARI M, DI LISIO L, et al: The Epstein Barr-encoded BART-6-3p microRNA affects regulation of Cell growth and immuno response in Burkitt lymphoma. Infect Agent Cancer 9: 12, 2014.
132. RAMAKRISHNAN R, DONAHUE H, GARCIA D, et al: Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of nasal NK T Cell lymphomas. PLoS One 6: E27271, 2011.
133. HSU CY, YI YH, CHANG KP, CHANG YS, CHEN SJ and CHEN HC: The Epstein-Barr virus-encoded microRNA miR-BART9 promotes tumor metastasis by targeting E-cadherin in nasopha-ryngeal carcinoma. PLoS Pathog 10: E1003974, 2014.
134. ROSS N, GANDHI MK and NOURSE JP: The Epstein-Barr virus microRNA BART11-5p targets the early B-cell transcription factor EBF1. Am J Blood Res 3: 210-224, 2013.
135. HANEKLAUS M, GERLIC M, KUROWSKA-STOLARSKA M, et al: Cutting edge: Mir-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J Immunol 189: 3795-3799, 2012.
136. JUNG YJ, CHOI H, KIM H and LEE SK: MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BzLF1 and BRLF1. J Virol 88: 9027-9037, 2014.
137. LIN TC, LIU TY, HSU SM and LIN CW: Epstein-Barr virus-encoded miR-BART20-5p inhibits T-bet translation with secondary suppression of p53 in invasive nasal NK/T-cell lymphoma. Am J Pathol 182: 1865-1875, 2013.
138. LUNG RW, TONG JH, SUNG YM, et al: Modulation of LMP2A expression by a newly identifed Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 11: 1174-1184, 2009.